BACKGROUND:Women with polycystic ovarian syndrome (PCOS) are intrinsically insulin resistant and have a high risk of cardiovascular disease and type 2 diabetes. Weight loss improves risk factors, but the optimal diet composition is unknown. Low-glycemic index (low-GI) diets are recommended without evidence of their clinical effectiveness. OBJECTIVE: We compared changes in insulin sensitivity and clinical outcomes after similar weight losses after consumption of a low-GI diet compared with a conventional healthy diet in women with PCOS. DESIGN: We assigned overweight and obese premenopausal women with PCOS (n = 96) toconsume either an ad libitum low-GI diet or a macronutrient-matched healthy diet and followed the women for 12 mo or until they achieved a 7% weight loss. We compared changes in whole-body insulin sensitivity, which we assessed using the insulin sensitivity index derived from the oral-glucose-tolerance test (ISI(OGTT)); glucose tolerance; body composition; plasma lipids; reproductive hormones; health-related quality of life; and menstrual cycle regularity. RESULTS: The attrition rate was high in both groups (49%). Among completers, ISI(OGTT) improved more with the low-GI diet than with the conventional healthy diet (mean +/- SEM: 2.2 +/- 0.7 compared with 0.7 +/- 0.6, respectively; P = 0.03). There was a significant diet-metformin interaction (P = 0.048), with greater improvement in ISI(OGTT) among women prescribed both metformin and the low-GI diet. Compared with women who consumed the conventional healthy diet, more women who consumed the low-GI diet showed improved menstrual cyclicity (95% compared with 63%, respectively; P = 0.03). Among the biochemical measures, only serum fibrinogen concentrations showed significant differences between diets (P < 0.05). CONCLUSION: To the best of our knowledge, this study provides the first objective evidence to justify the use of low-GI diets in the management of PCOS.
RCT Entities:
BACKGROUND:Women with polycystic ovarian syndrome (PCOS) are intrinsically insulin resistant and have a high risk of cardiovascular disease and type 2 diabetes. Weight loss improves risk factors, but the optimal diet composition is unknown. Low-glycemic index (low-GI) diets are recommended without evidence of their clinical effectiveness. OBJECTIVE: We compared changes in insulin sensitivity and clinical outcomes after similar weight losses after consumption of a low-GI diet compared with a conventional healthy diet in women with PCOS. DESIGN: We assigned overweight and obese premenopausal women with PCOS (n = 96) to consume either an ad libitum low-GI diet or a macronutrient-matched healthy diet and followed the women for 12 mo or until they achieved a 7% weight loss. We compared changes in whole-body insulin sensitivity, which we assessed using the insulin sensitivity index derived from the oral-glucose-tolerance test (ISI(OGTT)); glucose tolerance; body composition; plasma lipids; reproductive hormones; health-related quality of life; and menstrual cycle regularity. RESULTS: The attrition rate was high in both groups (49%). Among completers, ISI(OGTT) improved more with the low-GI diet than with the conventional healthy diet (mean +/- SEM: 2.2 +/- 0.7 compared with 0.7 +/- 0.6, respectively; P = 0.03). There was a significant diet-metformin interaction (P = 0.048), with greater improvement in ISI(OGTT) among women prescribed both metformin and the low-GI diet. Compared with women who consumed the conventional healthy diet, more women who consumed the low-GI diet showed improved menstrual cyclicity (95% compared with 63%, respectively; P = 0.03). Among the biochemical measures, only serum fibrinogen concentrations showed significant differences between diets (P < 0.05). CONCLUSION: To the best of our knowledge, this study provides the first objective evidence to justify the use of low-GI diets in the management of PCOS.
Authors: Amy M Goss; Paula C Chandler-Laney; Fernando Ovalle; Laura Lee Goree; Ricardo Azziz; Renee A Desmond; G Wright Bates; Barbara A Gower Journal: Metabolism Date: 2014-07-18 Impact factor: 8.694
Authors: J M W Wong; M Gallagher; H Gooding; H A Feldman; C M Gordon; D S Ludwig; C B Ebbeling Journal: Pediatr Obes Date: 2015-07-01 Impact factor: 4.000
Authors: Barbara A Gower; Paula C Chandler-Laney; Fernando Ovalle; Laura Lee Goree; Ricardo Azziz; Renee A Desmond; Wesley M Granger; Amy M Goss; G Wright Bates Journal: Clin Endocrinol (Oxf) Date: 2013-05-20 Impact factor: 3.478
Authors: S Jafari-Sfidvajani; R Ahangari; M Hozoori; H Mozaffari-Khosravi; H Fallahzadeh; A Nadjarzadeh Journal: J Endocrinol Invest Date: 2017-11-06 Impact factor: 4.256
Authors: Anuja Dokras; David B Sarwer; Kelly C Allison; Lauren Milman; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; Jennifer Fleming; Christos Coutifaris; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2016-06-02 Impact factor: 5.958
Authors: Sydney K Willis; Lauren A Wise; Amelia K Wesselink; Kenneth J Rothman; Ellen M Mikkelsen; Katherine L Tucker; Ellen Trolle; Elizabeth E Hatch Journal: Am J Clin Nutr Date: 2020-07-01 Impact factor: 7.045